Nabsys develops a High-Definition Genome Mapping Platform for electronic whole-genome mapping. The company plans to offer that platform through an early access program in the first half of 2023. Nabsys raised $13M in the most recent tranche, part of an expanded $38M equity funding round. The financing will be used to accelerate growth and to expand operations and the team. Led by founder and CEO Barrett Bready, M.D., Nabsys employs an interdisciplinary group of scientists, engineers, and other professionals focused on improving genomic structural variation analysis to increase diagnostic yield and improve patient outcomes. The company is located in Providence, RI. Nabsys develops an electronic High-Definition Mapping (HDM) platform for whole-genome mapping. The company employs electronic detection to deliver high-resolution single-molecule measurements and make long-range structural information accessible to laboratories. Its HD-Mapping approach aims to offer cost-effective hardware and consumables. Nabsys plans to complete development and commercialize a second-generation HDM platform. The company also intends to increase headcount in R&D, manufacturing, and global commercial operations. Nabsys is led by founder and CEO Barrett Bready, M.D. Nabsys develops the HD‑Mapping whole-genome electronic mapping platform using proprietary electronic nanochannel detectors to analyze long DNA molecules at high velocity. Its electronic mapping enables routine, scalable analysis of genomic structural variation. HD‑Mapping has applications in de novo assembly, structural variant analysis, metagenome characterization, strain identification and next-generation cytogenetics. The company is led by founder and CEO Barrett Bready. Nabsys closed a $21M equity funding round and intends to use the funds to finalize product development and support a global commercial launch of its platform. The company is based in Providence, RI. Nabsys develops a solid-state, single-molecule positional sequencing platform that uses nanodetectors to analyze single DNA molecules, revealing both location and identity of DNA sequences over long distances. The system is designed to aid analysis of genome structural variation, genome mapping, and both targeted and whole genome sequencing. Nabsys says its platform can help genomic researchers correctly and quickly assemble short DNA sequences generated by existing sequencing technologies and analyze structural variation in a high-throughput way. Led by Barrett Bready, M.D., as president and chief executive officer, the company plans to commercially launch its positional sequencing system. The recent financing will be used to support that launch and initial applications in genome assembly, finishing, and structural-variation analysis. The company is based in Providence, Rhode Island. NABsys develops proprietary solid‑state electronic systems intended for single‑molecule DNA sequencing and related DNA analysis, coupling semiconductor hardware with chemistry and algorithms. The platform is designed to reveal long‑range DNA sequence information and to improve accuracy, speed, cost and scalability versus existing sequencing technologies. Target applications mentioned include analysis of DNA structural variation, targeted gene sequencing, and whole‑genome sequencing, with an eye toward enabling clinical whole‑genome applications. The company says the platform will deliver information content not attainable from other DNA sequencing platforms. NABsys was the first company to receive a “$1000 Genome” award from the National Human Genome Research Institute for an electronic sequencing approach. The new financing will support continued technology development and commercialization.

Total raised

$96M

Funding rounds

6

Latest round

Equity

Latest activity

Nov 2022